GSK Gives Affymax Independence: Company To File IND, IPO In Three Years
Executive Summary
Affymax Research Institute is re-emerging from GlaxoSmithKline as an independent company with the goal of filing its first IND by the middle of the decade.
You may also be interested in...
Bayer Spins Off Respiratory Products To Former Execs At Aerovance
Bayer is spinning off rights to several respiratory products in development to Aerovance, a start-up biotech company led by former Bayer executives
Bayer Spins Off Respiratory Products To Former Execs At Aerovance
Bayer is spinning off rights to several respiratory products in development to Aerovance, a start-up biotech company led by former Bayer executives
Cashing in on Affymetrix
GSK recorded $216 mil. in profits from a reduction in its holdings in Affymetrix during the first half of 2000. Glaxo acquired 65% of Affymetrix as part of the $485 mil. purchase of Affymax in 1995. Glaxo sold additional shares of Affymetrix in the second half of the year, which contributed to an additional $280 mil. in profits from equity investments. GSK now owns 16% of the company, and has surrendered its right to board representation